Motif Bio PLC Results of Two Posters on Iclaprim at ID Week 2015
13 Ottobre 2015 - 8:00AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
13 October 2015
13 October 2015
Motif Bio plc
("Motif" or the "Company")
Announces Results of Two Posters on Iclaprim at ID Week 2015
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, today
announced results of two iclaprim clinical studies that were
presented at the Infectious Disease Week 2015 (ID Week) conference
in San Diego, California on 9 October, 2015. Iclaprim is a novel
antibiotic, targeting the bacterial dihydrofolate reductase enzyme,
which is currently starting two Phase III clinical trials to treat
acute bacterial skin and skin structure infections (ABSSSI).
Dr. David Huang, Chief Medical Officer at Motif, commented:
"Data from these studies provides us with further confidence that
iclaprim can perform well in the two Phase III trials in ABSSSI.
Furthermore, the Phase II data in nosocomial pneumonia caused by
Gram-positive bacteria, which are commonly identified as
Staphylococcus aureus, including MRSA, provides good evidence that
iclaprim may also be successful in our planned Phase III clinical
trials to treat hospital-acquired and ventilator-associated
bacterial pneumonia."
The two posters:
(1) "Cessation of Spread of Lesion and Absence of Fever at 72
hours in Complicated Skin and Skin Structure Infection (cSSSI):
Reanalysis of the Combined ASSIST Phase III Study Comparing
Iclaprim and Linezolid."
This poster presented data on the reanalysis of two Phase III
studies to treat cSSSI comparing iclaprim to linezolid, a standard
of care treatment for SSSI, using endpoints similar to those based
on the US Food and Drug Administration's (FDA) recently changed
guidelines for ABSSSI trials.
In the first Phase III study, patients who received iclaprim and
linezolid had an early clinical response, defined as cessation of
lesion spread and fever resolution at 72 hours of 73.9% and 71.4%,
respectively: difference 2.5%; 95% confidence interval -5.6% to
10.6%.
In the second Phase III study, patients treated under the same
treatment regimen had an early clinical response of 73.3% and
73.7%, respectively: difference -0.4%; 95% confidence interval
-8.4% to 7.7%.
These data show that iclaprim achieved a high rate of early
clinical response among patients with cSSSI.
(2) "Randomized, Double-Blind, Multicenter Phase II Study to
Evaluate Efficacy and Safety of Intravenous Iclaprim versus
Vancomycin in the Treatment of Hospital-Acquired,
Ventilator-Associated, or Health-Care-Associated Pneumonia
Suspected or Confirmed Caused by Gram-positive Pathogens."
This poster presented data on outcomes related to treatment with
iclaprim compared to vancomycin, a standard of care treatment for
Hospital-acquired bacterial pneumonia (HABP), ventilator-associated
pneumonia (VAP) and healthcare-associated pneumonia (HCAP).
Patients who received a low dose of iclaprim, a high dose of
iclaprim, and vancomycin had a clinical cure rate of 73.9%, 62.5%,
and 52.2%, respectively. Under the same treatment regime patients
had a Day 28 mortality rate of 8.7%, 12.5%, and 21.7%,
respectively.
These data show that iclaprim had high clinical cure rates and
relatively low mortality rates among patients with HABP, VAP, and
HCAP.
Enquires:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive
Officer)
David Huang (Chief Medical Officer)
www.motifbio.com
Zeus Capital Limited (NOMINATED
ADVISER and BROKER)
Phil Walker/Dan Bate +44 (0) 20
Dominic Wilson 3829 5000
Northland Capital Partners Limited
(BROKER)
Patrick Claridge/ David Hignell +44 (0) 20
John Howes/ Mark Treharne (Broking) 7382 1100
+49 (0) 89
MC Services AG (TRADE PR) 210 2280
Raimund Gabriel +44 (0) 207
Shaun Brown 148 5998
Plumtree Capital Limited (FINANCIAL
ADVISOR) +44 (0) 207
Stephen Austin 183 2493
Yellow Jersey PR Limited (FINANCIAL
PR)
Charles Goodwin +44 (0) 7747
Dominic Barretto 788 221
Notes to Editors:
Motif is a clinical stage biopharmaceutical company, which
specialises in developing novel antibiotics designed to be
effective against serious and life-threatening infections caused by
multi-drug resistant bacteria.
Iclaprim, Motif's primary antibiotic product, is being developed
for the treatment of the most common and serious bacterial
infections such as acute bacterial skin and skin structure
infections (ABSSSI) and hospital acquired bacterial pneumonia
(HABP), including those caused by resistant strains such as MRSA
(methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug
resistant Streptococcus pneumoniae). These have become prevalent in
patients in both the community and hospital settings.
The Company is in discussions with pharmaceutical companies and
universities to build a pipeline of innovative antibiotics
targeting Gram-positive and Gram-negative bacteria.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFFEEFEFISEES
(END) Dow Jones Newswires
October 13, 2015 02:00 ET (06:00 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024